Analysis of 45 randomized controlled trials reveals vitamin D supplementation produces statistically significant but modest improvements in key cardiovascular risk factors. The meta-analysis found reductions in LDL cholesterol by 0.136 mmol/L, systolic blood pressure by 2.79 mmHg, fasting glucose by 0.11 mmol/L, and hemoglobin A1c by 0.164% compared to placebo. Age and baseline vitamin D status emerged as important modifiers—adults over 55 saw greater improvements in blood pressure and LDL cholesterol, while younger adults experienced better glucose control. These findings align with growing evidence that vitamin D's cardiovascular benefits may be most pronounced in deficient populations, supporting targeted rather than universal supplementation strategies. However, the clinical significance of these modest changes remains questionable for cardiovascular disease prevention. The reductions, while statistically significant, fall short of what's typically considered clinically meaningful—for instance, the 2.79 mmHg blood pressure reduction is well below the 10+ mmHg decreases seen with antihypertensive medications. As this remains a preprint awaiting peer review, these conclusions may change following formal evaluation. The research represents confirmatory rather than groundbreaking evidence in the ongoing vitamin D supplementation debate.